186
Participants
Start Date
July 28, 2023
Primary Completion Date
June 30, 2025
Study Completion Date
July 31, 2025
Placebo
Subject receives Placebo by subcutaneous injection daily for 28 days
ZT-01, 7 mg
Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
ZT-01, 15 mg
Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
ZT-01, 22 mg
Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
RECRUITING
Albany Medical Center, Albany
RECRUITING
MedStar Good Samaritan Hospital, Baltimore
RECRUITING
Lucas Research Inc., Morehead City
RECRUITING
East Coast Institute for Research, Macon
RECRUITING
East Coast Institute for Research LLC, Jacksonville
RECRUITING
Metabolic Research Institute, West Palm Beach
RECRUITING
Hanson Diabetes Center, Port Charlotte
RECRUITING
Suncoast Clinical Research, New Port Richey
RECRUITING
University Diabetes & Endocrine Consultants, Chattanooga
RECRUITING
IU Health University Hospital, Indianapolis
RECRUITING
University of Kansas Medical Center, Kansas City
RECRUITING
Southern Endocrinology Associates, Mesquite
RECRUITING
Diabetes & Glandular Disease Clinic, San Antonio
RECRUITING
Texas Diabetes & Endocrinology, PA, Austin
RECRUITING
Palm Research Center, Inc., Las Vegas
RECRUITING
USC Keck Medicine Eastside Center for Diabetes, Los Angeles
RECRUITING
Headlands Research, Escondido
RECRUITING
LCGK Research, San Carlos
RECRUITING
Centricity Research Calgary Endocrinology, Calgary
RECRUITING
BC Diabetes, Vancouver
WITHDRAWN
Centricity Research Barrie Endocrinology, Barrie
RECRUITING
Centricity Research Vaughan Endocrinology, Concord
RECRUITING
Centricity Research Etobicoke Endocrinology, Etobicoke
RECRUITING
Centricity Research Toronto, Toronto
RECRUITING
Mount Sinai Hospital: Leadership Sinai Centre for Diabetes, Toronto
Zucara Therapeutics Inc.
INDUSTRY